Search

Search Constraints

You searched for: Author/Creator Parekh, Samir

Search Results

1. 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. (9th November 2020)

2. 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. (9th November 2020)

3. 90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway. (9th November 2020)

4. 90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway. (9th November 2020)

6. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Issue 9 (28th July 2020)

7. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. (15th June 2022)

8. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Issue 12 (15th October 2021)

9. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Issue 12 (December 2018)